TITLE:
Effect of Hyoscine Butyl Bromide on the Course of Labour
AUTHORS:
Dauda Deba Barau, Eyaofun Teddy Agida, Olatunde Onafowokan, Francis Olayemi Adebayo
KEYWORDS:
Hyoscine Butyl Bromide, Labour, Prolonged Labour
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.8 No.12,
September
30,
2018
ABSTRACT: Background: Hyoscine butyl bromide
(Buscopan) is being used as an agent for reducing the duration of labour. There
are however conflicting results on the effect of this agent on cervical
dilation. Materials and Methods: This was an open label clinical trial of one hundred
and thirty two (132) pregnant women in labour. Women were grouped to receive
either 20 mg of hyoscine butyl bromide intramuscularly at the onset of active phase
labour or placebo “Normal saline”. The main outcome measure was to compare the
duration of first stage labour in the study and control groups as well as
feto-maternal outcomes. Relevant data were collected using a proforma. The data
were analysed using Statistical Package for Social Sciences (SPSS) version
20. Results: A total of 132 were randomised and 123 yielded for
analysis. Of these 59 received hyoscine butyl bromide and 64 received placebo.
There was no significant difference in the mean duration of active labour to
second stage between the drug and placebo arms (312.5 versus 305.3 minutes,
respectively, P = 0.788). The feto-maternal outcomes were similar between both arms. Conclusion: Hyoscine butyl bromide does not shorten the duration
of labour in spontaneous labour. It also does not change feto-maternal outcomes.